| Page 3 | Aplastic Anemia and MDS International Foundation

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

Author(s): 
Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U
Primary Author: 
Balaian E
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2017

The effects of

Bone Marrow Diseases: 

Cancer specialist shares a diagnosis close to home

“I want you to talk to me like I’m one of your patients, not like I’m your mother.”

My mom’s familiar voice came over the car’s speakers via the Bluetooth connection to my phone as I drove home. She had left a voicemail an hour earlier asking me to call her back, which was never a good sign. My mother, still working as an administrator in Rhode Island at age 74, was not the type to mince words, nor ask for a return call to discuss trivialities. I asked her what was going on.

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.
Event Date: 
Sat, 11/04/2017 -
8:00am to 3:30pm
Conference Event Type: 

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

Author(s): 
Zhao X, Feng X, Wu Z, Winkler T, Desmond R, Olnes M, Dumitriu B, Townsley DM, Dunbar CE, Young NS
Primary Author: 
Zhao X
Journal Title: 
Exp Hematol
Original Publication Date: 
Sep 2017

Although hematopoietic growth factors are found at high levels in

Bone Marrow Diseases: 

Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

Author(s): 
Mies A, Platzbecker U
Primary Author: 
Mies A
Journal Title: 
Semin Hematol
Original Publication Date: 
Jul 2017

Patients with lower-risk

Bone Marrow Diseases: